Report

High-Resolution Melting Analysis Market Analysis

The high-resolution melting analysis market size stands at USD 277.04 million in 2025 and is forecast to grow to USD 342.11 million in 2030, advancing at a 4.31% CAGR over 2025-2030. Strong uptake of precision-medicine programs, broader reimbursement for genetic tests, and a clear cost advantage over next-generation sequencing are sustaining demand. Established molecular-diagnostics suppliers keep introducing integrated platforms that combine HRM, digital PCR, and cloud analytics to cut manual steps, speed turnaround, and lower per-test cost. Infectious-disease surveillance programs in Asia-Pacific and Latin America are creating new, high-throughput use cases, while point-of-care innovators are pushing compact instruments into clinics that lack molecular-testing expertise. Meanwhile, labor shortages in clinical labs are accelerating automation, cementing HRM's position as an accessible, cost-effective genotyping workhorse.

Global High-Resolution Melting Analysis Market Trends and Insights



Growing Adoption of Precision Medicine Initiatives

Precision-medicine programs now stretch well beyond oncology into cardiology, psychiatry, and chronic-disease management, and they rely heavily on rapid gene-drug matching assays. The US Centers for Medicare & Medicaid Services proposed coverage for pharmacogenomic testing, enabling HRM platforms to secure reimbursement for clinically actionable variants. Leading payers such as UnitedHealthcare have started aligning policies that grant consistent coverage once clinical utility is proven, creating a stable revenue stream for HRM reagent vendors. Diagnostic manufacturers respond by embedding HRM modules into cartridge-based workflows that deliver genotyping results in under an hour, as illustrated by QIAGEN's QIAstat-Dx expansion into companion diagnostics. The combination of lower test cost, quicker turnaround, and billing clarity is driving hospital labs to replace Sanger sequencing in routine drug-response panels, thereby broadening the installed base.

Expansion of Genetic Testing Reimbursement Policies

Payers in the United States and Europe are shifting from restrictive, indication-specific rules toward evidence-based frameworks that reward analytical accuracy and clinical usefulness. An American Journal of Managed Care study tracking 110 health-plan policies showed that plans covering ?15 actionable drug-gene pairs doubled between 2023 and 2025. HRM systems gain because they reach sensitivity thresholds at a fraction of sequencing's price, which suits high-volume screening. EU payer cooperation under the European Network for Health Technology Assessment has further accelerated cross-border reimbursement decisions, giving multinational labs a uniform outlook. Large platform suppliers capitalize by bundling HRM reagents with cloud portals that auto-generate insurer-ready reports, reducing administrative overhead in small community hospitals.

High Capital Investment Required for HRM Instrumentation

Entry-level HRM platforms cost between USD 60,000 and USD 120,000, excluding service contracts, a hurdle for small labs whose reimbursement flows remain volatile. Staffing shortages compound the problem; one 2024 survey found 29.1% of US clinical labs reported difficulty retaining technologists, pushing management to delay equipment upgrades. Digital-twin projects show promise in boosting utilization and lowering amortized cost per test, yet such workflow-optimization software adds another USD 100,000-200,000, keeping total investment high. Financing solutions such as reagent-rental agreements are emerging, but interest-rate hikes since 2024 have raised leasing costs, limiting uptake in low-margin public hospitals.

Other drivers and restraints analyzed in the detailed report include:

Surge in Companion Diagnostics Development Pipelines / Increasing Government Funding for Genomic Surveillance Programs / Limited Standardization of Assay Protocols Across Laboratories /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Reagents and consumables generated the largest revenue in 2024, contributing 49.54% due to recurring refill demand that scales with installed instruments. The High-Resolution Melting Analysis market size attributable to reagents reached USD 137.4 million, and the category is forecast to maintain steady mid-single-digit growth as assay menus widen. Instrument revenue is accelerating at a 6.53% CAGR because multisite health systems invest in unified, automated analyzers that slash technician time and standardize quality across campuses. Manufacturers now bundle instruments with cloud licenses and validated assays, creating all-inclusive contracts that align with outcome-based procurement models. Software and service revenue, although still below 10% of overall value, is climbing fastest in mature markets where labs outsource data interpretation to vendor-operated platforms that guarantee 24/7 support.

The High-Resolution Melting Analysis Market Report is Segmented by Product & Service (Reagents & Consumables, Instruments, and Software & Services), Application (SNP Genotyping, and More), End-User (Research Laboratories & Academic Institutes, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America produced 41.56% of global revenue in 2024, underpinned by well-funded reference labs, payer policies that cover actionable gene-drug pairs, and a consolidated supplier base that offers nationwide service contracts. The region's demand is also buoyed by high companion-diagnostic trial activity, which funnels large volumes into contract research organizations equipped with fully automated HRM suites. Workforce shortages remain a challenge; US lab-technologist vacancy rates surpassed 46% in 2024, prompting networks to adopt instruments with walk-away workflows that minimize human intervention.

Asia-Pacific is the fastest-growing territory, projected at a 5.45% CAGR through 2030, propelled by universal-health-coverage programs and government-funded genomic initiatives such as Australia's USD 500.1 million Genomics Health Futures Mission. China's hospital-procurement reforms, which favor cost-effective domestic diagnostics, are encouraging local joint ventures that bundle HRM instruments with government-approved reagent menus. Mobile point-of-care pilots in India and the Philippines showcase cartridge-based HRM tests that run off battery packs, broadening access in regions lacking central labs.

Europe commands solid demand thanks to a dense network of academic medical centers and a supportive reimbursement climate for pharmacogenomics. The EU Medical Device Regulation harmonizes post-market surveillance, aiding suppliers in launching pan-European HRM kits. Hospitals in Germany and France are integrating cloud-based analytics that route anonymized melt-curve data into national bio-bank repositories, accelerating translational research links between genomic findings and therapy outcomes.

Middle East & Africa and South America collectively capture under 10% of revenue but record double-digit test-volume growth as infectious-disease programs seek rapid genotyping to guide outbreak response. Deployment of HRM-equipped mobile vans during the 2024 Rift Valley fever outbreak in Kenya cut sample processing times from five days to same day, reinforcing demand for ruggedized platforms in remote regions.

List of Companies Covered in this Report:

Thermo Fisher Scientific / Bio-Rad Laboratories / QIAGEN / Agilent Technologies / Roche / Illumina / Azura Genomics / Canon / bioMerieux / Meridian Bioscience / New England Biolabs / Promega / LGC Biosearch Technologies / Takara Bio / Cepheid (Danaher) / Fluidigm / Analytik Jena / Pacific Bioscience / Sysmex /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /